Zogenix, Inc. has been acquired by UCB.  |  U.S. FDA Approved a new indication for FINTEPLA® (fenfluramine).   Learn More

Rare Disease TherapiesTogether, we can bring hope and support to families impacted by rare diseases.

Together, we’re rewriting rare.

Zogenix is committed to developing and commercializing transformative therapies to improve the lives of patients and their families living with rare diseases.

Clinical Trials

To view our open or completed clinical trials, please visit www.clinicaltrials.gov (U.S.) or www.clinicaltrialsregister.eu (EU) and search Zogenix.